Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection

REB23-1733

This is a single-patient, phase I/II clinical trial that aims to evaluate the potential of a bacteriophage cocktail to treat and prevent the recurrence of a methicillin-susceptible Staphylococcus aureus prosthetic joint infection of the hip. The patient has exhausted all conventional therapies, both surgical and medical, at considerable detriment to his quality of life. The treatment involves a one time, intra-operative injection of bacteriophages into the joint and 14 days of intravenous phage therapy. The goal is to eliminate the infection and prevent further complications, providing a potential new treatment avenue for patients with difficult-to-treat infections.

2024-06-01

2025-06-01

2025-06-01

Not yet recruiting

Early phase I

1

Inclusion Criteria: * Diagnosis of active chronic prosthetic joint infection * Causative bacteria is susceptible to bacteriophage therapy in vitro * History of multiple failed antibiotic and surgical interventions Exclusion Criteria: * Stage 5 chronic kidney disease * Cirrhosis * A known allergy to phage products * Fever * Involvement in another clinical trial * Pregnancy

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE1', 'PHASE2'], 'designInfo': {'allocation': 'NA', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Single patient', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}, 'enrollmentInfo': {'count': 1, 'type': 'ESTIMATED'}}

2024-06-13